Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GILD 
Gilead Sciences Inc (GILD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: GILD (3-star) is a STRONG-BUY. BUY since 29 days. Profits (0.31%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
30 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $116.77
1 Year Target Price $116.77
| 15 | Strong Buy |
| 4 | Buy |
| 11 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 10.58% | Avg. Invested days 36 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 142.48B USD | Price to earnings Ratio 23.03 | 1Y Target Price 116.77 |
Price to earnings Ratio 23.03 | 1Y Target Price 116.77 | ||
Volume (30-day avg) 30 | Beta 0.31 | 52 Weeks Range 68.02 - 118.28 | Updated Date 07/12/2025 |
52 Weeks Range 68.02 - 118.28 | Updated Date 07/12/2025 | ||
Dividends yield (FY) 2.85% | Basic EPS (TTM) 4.76 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 20.76% | Operating Margin (TTM) 38.49% |
Management Effectiveness
Return on Assets (TTM) 12.14% | Return on Equity (TTM) 32.65% |
Valuation
Trailing PE 23.03 | Forward PE 13.79 | Enterprise Value 153410388826 | Price to Sales(TTM) 4.96 |
Enterprise Value 153410388826 | Price to Sales(TTM) 4.96 | ||
Enterprise Value to Revenue 5.34 | Enterprise Value to EBITDA 14.5 | Shares Outstanding 1243929984 | Shares Floating 1241354188 |
Shares Outstanding 1243929984 | Shares Floating 1241354188 | ||
Percent Insiders 0.1 | Percent Institutions 89.6 |
Upturn AI SWOT
Gilead Sciences Inc
Company Overview
History and Background
Gilead Sciences Inc. was founded in 1987. Initially focused on antiviral research, it achieved significant milestones with drugs for HIV/AIDS, viral hepatitis, and influenza, evolving into a major biopharmaceutical company.
Core Business Areas
- HIV: Development and commercialization of therapies for HIV infection, including single-tablet regimens and long-acting injectables.
- Liver Diseases: Focuses on therapies for chronic liver diseases, primarily viral hepatitis (HBV and HCV) and liver cancer.
- Oncology: Developing and marketing therapies for various cancers.
- Other: Includes other therapeutic areas such as inflammation and respiratory diseases.
Leadership and Structure
Daniel O'Day is the Chairman and Chief Executive Officer. The organizational structure includes dedicated teams for research, development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Biktarvy: A single-tablet regimen for HIV treatment. Holds a significant market share in the HIV treatment landscape. Competitors include GSK's Dovato and ViiV Healthcare.
- Descovy: Used for HIV pre-exposure prophylaxis (PrEP). Faces competition from generic versions of Truvada and alternative PrEP options. It has a significant amount of market share.
- Vemlidy: Treatment for chronic hepatitis B virus (HBV) infection. Faces competition from other HBV therapies. It has a lower market share when compared to Vemlidy.
- Trodelvy: A treatment for certain types of breast cancer. It has growing market share in a specialized cancer treatment niche. Competitors include other targeted therapies and chemotherapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory oversight, and intense competition. Focus is on drug discovery, clinical trials, manufacturing, and commercialization of innovative therapies.
Positioning
Gilead is a leading biopharmaceutical company with a strong position in antiviral therapies and expanding presence in oncology. Competitive advantages include established brands, research expertise, and strategic acquisitions.
Total Addressable Market (TAM)
The TAM for Gilead's key therapeutic areas, including HIV, liver diseases, and oncology, is estimated to be in the hundreds of billions of dollars. Gilead is positioned to capture a significant share through its existing products and pipeline.
Upturn SWOT Analysis
Strengths
- Strong portfolio of HIV drugs
- Expertise in antiviral research and development
- Established commercial infrastructure
- Strong cash flow generation
- Strategic Acquisitions
Weaknesses
- Reliance on HIV franchise
- Patent expirations on key drugs
- Competition from generics
- Pipeline risks associated with drug development
- Dependence on large acquisitions for growth
Opportunities
- Expansion into new therapeutic areas like oncology
- Development of long-acting HIV therapies
- Strategic partnerships and acquisitions
- Emerging markets growth
- Advancements in diagnostics and personalized medicine
Threats
- Generic competition
- Biosimilar competition
- Pricing pressure and reimbursement challenges
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- AbbVie (ABBV)
- Johnson & Johnson (JNJ)
- Merck & Co., Inc. (MRK)
- GSK plc (GSK)
Competitive Landscape
Gilead possesses strong antiviral expertise, however, it must navigate increasing competition in HIV and oncology.
Major Acquisitions
Kite Pharma
- Year: 2017
- Acquisition Price (USD millions): 11900
- Strategic Rationale: Expanded Gilead's presence in oncology with cell therapy platform.
Immunomedics
- Year: 2020
- Acquisition Price (USD millions): 21000
- Strategic Rationale: Added Trodelvy, a promising cancer therapy, to Gilead's portfolio.
Growth Trajectory and Initiatives
Historical Growth: Gilead has experienced growth driven by its HIV franchise and acquisitions. Growth rates have fluctuated due to patent expirations and competition.
Future Projections: Analyst estimates suggest continued growth driven by oncology and other therapeutic areas. Specific growth rates vary depending on analyst forecasts.
Recent Initiatives: Recent initiatives include acquisitions in oncology, development of new HIV therapies, and expansion into new markets.
Summary
Gilead Sciences is a strong biopharmaceutical company with a dominant position in HIV. The company's oncology pipeline, aided by acquisitions, is key to future growth. Patent expirations and increasing competition in existing markets pose challenges, requiring successful pipeline development and strategic initiatives for long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered financial advice. Market data are estimates and may not reflect actual figures. Investing involves risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Gilead Sciences Inc
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 1992-01-22 | Chairman & CEO Mr. Daniel P. O'Day | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 17600 | Website https://www.gilead.com |
Full time employees 17600 | Website https://www.gilead.com | ||
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.